195 related articles for article (PubMed ID: 31851093)
1. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial.
Zhang Y; Zhu YJ; Zhao Z; Zhao JT; Wang TY; Yang J; Chen DF; Lan CH
Eur J Gastroenterol Hepatol; 2020 May; 32(5):563-568. PubMed ID: 31851093
[TBL] [Abstract][Full Text] [Related]
2. A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial.
Tai WC; Liang CM; Kuo CM; Huang PY; Wu CK; Yang SC; Kuo YH; Lin MT; Lee CH; Hsu CN; Wu KL; Hu TH; Chuah SK
J Antimicrob Chemother; 2019 Jun; 74(6):1718-1724. PubMed ID: 30768161
[TBL] [Abstract][Full Text] [Related]
3. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
Puig I; González-Santiago JM; Molina-Infante J; Barrio J; Herranz MT; Algaba A; Castro M; Gisbert JP; Calvet X
Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869699
[TBL] [Abstract][Full Text] [Related]
4. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
5. Fourteen-Day Tegoprazan-Amoxicillin Dual Therapy as the First-Line Treatment of Helicobacter pylori Infection (SHARE2301): A Multicenter, Noninferiority, Randomized Clinical Trial.
Kong Q; Mirza IA; Zhang X; Song X; Li X; Zhang Q; Xu L; Guo Y; Yu Y; Zuo X; Li Y; Li Y
Helicobacter; 2024; 29(3):e13098. PubMed ID: 38853394
[TBL] [Abstract][Full Text] [Related]
6. Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14-day regimen?
Zullo A; Fiorini G; Scaccianoce G; Portincasa P; De Francesco V; Vassallo R; Urban F; Monica F; Mogavero G; Amato A; Vaira D
J Gastrointestin Liver Dis; 2019 Mar; 28(1):11-14. PubMed ID: 30851166
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial.
Song Z; Zhou L; Xue Y; Suo B; Tian X; Niu Z
Helicobacter; 2020 Dec; 25(6):e12762. PubMed ID: 33040439
[TBL] [Abstract][Full Text] [Related]
8. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial.
Yu L; Luo L; Long X; Liang X; Ji Y; Graham DY; Lu H
Helicobacter; 2019 Aug; 24(4):e12596. PubMed ID: 31111580
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.
Bi H; Chen X; Chen Y; Zhao X; Wang S; Wang J; Lyu T; Han S; Lin T; Li M; Yuan D; Liu J; Shi Y
Chin Med J (Engl); 2022 Jul; 135(14):1707-1715. PubMed ID: 36193978
[TBL] [Abstract][Full Text] [Related]
10. Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States.
Graham DY; Javed SU; Keihanian S; Abudayyeh S; Opekun AR
J Gastroenterol; 2010 Aug; 45(8):816-20. PubMed ID: 20195646
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
Hu TH; Chuah SK; Hsu PI; Wu DC; Tai WC; Chiu YC; Wu KL; Kuo CM; Hu ML
Am J Med Sci; 2011 Sep; 342(3):177-81. PubMed ID: 21804375
[TBL] [Abstract][Full Text] [Related]
12. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection.
Mestrovic A; Perkovic N; Bozic J; Pavicic Ivelja M; Vukovic J; Kardum G; Puljiz Z; Tonkic A
PLoS One; 2020; 15(12):e0244500. PubMed ID: 33378403
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication.
Tepeš B; Vujasinović M; Šeruga M; Stefanovič M; Forte A; Jeverica S
Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):676-83. PubMed ID: 26862930
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.
Chuah SK; Liang CM; Lee CH; Chiou SS; Chiu YC; Hu ML; Wu KL; Lu LS; Chou YP; Chang KC; Kuo CH; Kuo CM; Hu TH; Tai WC
Medicine (Baltimore); 2016 May; 95(19):e3586. PubMed ID: 27175657
[TBL] [Abstract][Full Text] [Related]
16. Two-week Triple Therapy with either Standard or High-dose Esomeprazole for First-line H. pylori Eradication.
De Francesco V; Ridola L; Hassan C; Bellesia A; Alvaro D; Vaira D; Zullo A
J Gastrointestin Liver Dis; 2016 Jun; 25(2):147-50. PubMed ID: 27308644
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
Wu DC; Hsu PI; Tseng HH; Tsay FW; Lai KH; Kuo CH; Wang SW; Chen A
Medicine (Baltimore); 2011 May; 90(3):180-185. PubMed ID: 21512411
[TBL] [Abstract][Full Text] [Related]
18. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
[TBL] [Abstract][Full Text] [Related]
19. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Song Z; Zhou L; Zhang J; He L; Bai P; Xue Y
Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
[TBL] [Abstract][Full Text] [Related]
20. [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection].
Campillo A; Amorena E; Ostiz M; Kutz M; LaIglesia M
Gastroenterol Hepatol; 2016 Nov; 39(9):584-589. PubMed ID: 27084668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
